The significant outperformance of Regeneron Pharmaceuticals over the past two decades, as highlighted by its average annual return of 23.84% and the substantial growth of an initial $100 investment into $7,527.35, underscores the company's strong market position and potential for continued growth. This historical performance is likely to positively influence investor perception and could lead to increased investor confidence in the short term.